Figure 11.

PT150 reduces the severity of immune responses and lung pathology in animals infected with SARS-CoV-2. Modeling of SARS-CoV-2 driven pathological changes in lung tissue (A) shows concurrent increases in SARS-CoV-2 viral nucleocapsid protein intensity and CD4⁺ populations early in the course of infection (3 DPI) followed by increases in IL-6 production and IBA1⁺ cell populations at 5 DPI (B). Therapeutic treatment utilizing PT150 decreased the severity of all pathologic responses measured, based on the area under the curve (AUC) for SARS-CoV-2 (C), CD4⁺ cells (D), IL-6 (E), and IBA1⁺ cells (F).